Social inequities in oncology are driven by intersecting determinants of health and healthcare at multiple levels. Inequalities in the social determinants of health (SDOH) result in delayed cancer diagnoses, sub-optimal treatment, and increased mortality rates in patients with lower socioeconomic status (SES). This article describes the SDOH that influence the field of oncology, with the aim of identifying inadequacies in clinical practice and research, and raising awareness among key stakeholders. Some SDOH cannot be modified (age, race, sex and gender), while others are considered modifiable (lifestyle, diet, exercise, unwanted loneliness, economic resources). We have developed practical recommendations for national policymakers, hospital management, healthcare professionals (HCPs), and patients that address the root causes of social disparities in cancer care. HCPs within multidisciplinary teams who manage patients with cancer are in a key position to consider and address the SDOH that impact patients, particularly those of lower SES, in the clinical oncological setting.
10 January 2026 in Clinical and Translational Oncology
Introduction Social determinants of health (SDOH) significantly influence cancer development, treatment response, and clinical outcomes. However, their integration into oncology clinical practice remains limited. In this study, the perceptions of oncology health care professionals regarding the influence of SDOH and the existing barriers to addressing them within the Spanish health care system. Materials and methods This cross-sectional study was conducted using a self-administered questionnaire distributed to oncology professionals in various autonomous communities in Spain. Sociodemographic variables, professional roles, perceptions of the impact of SDOH, and perceived barriers to addressing these social factors were analyzed. Descriptive and inferential statistics (chi-square test and Fisher’s exact test) were applied. Results A total of 258 professionals, mainly from medical oncology, nursing, and oncology pharmacies, participated in the study. More than 80% considered that SDOH influences cancer development and prognoses, and nearly 70% considered that SDOH influences treatment toxicity. Significant differences in knowledge levels were identified by professional role, with the most significant lack of knowledge noted in nursing, pharmacy, and radiophysics. The main barriers reported were time constraints, resources, specific protocols, and training in social and cultural competencies. Conclusions There is a high level of awareness regarding the relevance of SDOH in oncology, although knowledge gaps and structural obstacles persist. Therefore, it is imperative to develop training and institutional interventions that integrate the social component into oncology care, thereby promoting more equitable and patient-centered clinical practice.
10 May 2026 in Clinical and Translational Oncology
Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR + /HER2 −) breast cancer (BC) is the most frequently diagnosed subtype of BC, accounting for approximately 70% of cases. The introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) has significantly improved clinical outcomes and transformed the therapeutic landscape of HR + /HER2 − in both the metastatic and early settings. Hepatotoxicity associated with CDK4/6i is increasingly recognized as a clinically relevant adverse event. Most cases are asymptomatic, occur early during treatment, and resolve with dose modification or management according to the Summary of Product Characteristics (SmPC). However, variability in monitoring and management persists in clinical practice. Key issues, such as corticosteroid use, treatment continuation and reintroduction of the CDK4/6i (either the same compound or another among the three globally approved agents) after liver toxicity recovery, remain insufficiently addressed by current evidence, despite the need for routine clinical decision-making. To address these gaps, a Spanish multidisciplinary panel of hepatologists and medical oncologists developed expert consensus recommendations on liver toxicity in patients with HR + /HER2 − BC receiving CDK4/6i. This consensus provides practical guidance on the classification, monitoring and management of liver-related adverse events during CDK4/6i therapy and promotes proactive collaboration between oncology and hepatology teams to support treatment continuity and optimize patient outcomes.